China Grants Dual mNGS Class III Medical Device Certificates, Accelerating Compliant Hospital Access

On August 31, 2026, China's metagenomic next-generation sequencing (mNGS) industry reached a historic turning point. In a single day, regulatory authorities approved two Class III medical device certificates for mNGS-based diagnostic kits, marking the formal transition from laboratory-developed tests (LDTs) to a new era of standardized, regulated in vitro diagnostic (IVD) commercialization.

The approvals represent the culmination of twelve years of technological refinement and clinical validation—a journey that began in 2014 when the New England Journal of Medicine published a landmark case demonstrating mNGS's ability to identify unknown pathogens and guide life-saving treatment. That same year, Peking Union Medical College Hospital partnered with BGI Genomics to launch China's first cerebrospinal fluid mNGS clinical study, ushering in what industry observers called the "Age of Exploration" for pathogen detection in China.

The two newly approved kits target distinct clinical applications. VISION MEDICALS, based in Guangzhou, received certification (Registration Number: 国械注准20263401813) for its respiratory pathogen nucleic acid detection kit using a combined probe anchoring polymerization sequencing method. Jinzhi Gene secured approval (Registration Number: 国械注准20263401810) for its bloodstream infection pathogen nucleic acid detection kit employing reversible terminator sequencing. The respiratory kit represents the world's first mNGS IVD approval in its category, while the bloodstream infection kit marks China's inaugural certification in that field.

The path to regulatory approval was neither swift nor straightforward. In late 2019, Chinese mNGS companies demonstrated the technology's potential by completing the novel coronavirus genome assembly and reporting in approximately 50 hours—a feat that propelled mNGS from laboratory curiosity to widespread clinical trial application. However, the technology's rapid adoption exposed significant quality control challenges.

The National Center for Clinical Laboratories (NCCL) conducted its first mNGS external quality assessment in 2021, and the results were sobering. The industry-wide pass rate was extremely low, with over 90% of laboratories grappling with both false-negative and false-positive results. False negatives proved particularly complex, influenced by sample quality, host nucleic acid interference, database limitations, and conversion efficiency of library preparation kits. False positives primarily stemmed from background bacterial contamination.

In response, leading mNGS companies collaborated with Nanjing Vazyme Biotech Co., Ltd., a prominent supplier of wet-lab solutions, to systematically address these challenges. The consortium standardized sample collection protocols, improved host nucleic acid removal during extraction, enhanced library preparation kit conversion rates, tightened background bacterial controls, and refined bioinformatics pipelines. These iterative improvements elevated inter-laboratory quality assessment pass rates from 41.8% to above 80%.

Vazyme has positioned itself as a critical enabler throughout this evolution, providing comprehensive mNGS wet-lab solutions that supported companies from methodology development through performance validation to regulatory submission. The company addressed three persistent pain points in mNGS workflows: turnaround time, background contamination, and detection sensitivity.

On the efficiency front, Vazyme reduced DNA library preparation time from 140 minutes to 80 minutes. For contamination control, the company implemented rigorous quality management across personnel, equipment, materials, methods, environment, and testing—minimizing host and environmental pathogen nucleic acid residue at the source. These improvements proved essential as the industry moved toward IVD compliance.

The regulatory breakthrough also aligns with policy developments. The National Healthcare Security Administration's release of the "Laboratory Testing Project Guidelines," combined with the dual certificate approvals, effectively unlocked the two "core keys" for mNGS compliance in hospital settings. This regulatory clarity is expected to trigger explosive demand for automation solutions.

Vazyme has responded with an integrated automation system designed for hospital deployment. The PANDA Ultra platform consolidates extraction, amplification, quantification, and purification modules into a single device—achieving true sample-in, library-out workflow without multi-equipment transfers or manual intervention. The system promises industrial-grade stability with academic-grade rigor, creating an end-to-end intelligent closed loop from raw sample to sequencing library.

According to the "Clinical Laboratory Standardized Application Guidelines for Metagenomic High-Throughput Sequencing Technology (2026 Edition)," detailed performance data for Vazyme's integrated solution will be released soon, providing hospitals with concrete validation metrics for procurement decisions.

The twelve-year journey from mNGS's first clinical application in 2014 to today's landmark approvals represents more than technological maturation—it signals China's commitment to building a regulated, evidence-based framework for advanced genomic diagnostics. For Vazyme and its IVD partners, the dual approvals are not an endpoint but a starting point. The company has pledged to continue anchoring its work in molecular biology fundamentals, delivering high-quality reagents and technical services as the industry navigates the next phase of compliance-driven growth.

As mNGS technology transitions from specialized laboratories to mainstream clinical practice, the standardization achieved through these approvals will likely serve as a model for other advanced diagnostic technologies seeking regulatory acceptance. The question now is not whether mNGS will become routine, but how quickly the ecosystem can scale to meet clinical demand while maintaining the quality standards that took more than a decade to establish.